GC Therapeutics has appointed Kate Haviland as Board Chair.
Kate was most recently President and CEO of Blueprint Medicines, where she also previously held the roles of Chief Operating Officer and Chief Business Officer prior to the company’s 2025 acquisition by Sanofi. Before joining Blueprint, Kate held a series of senior leadership roles at companies including Idera Pharmaceuticals, Sarepta Therapeutics, PTC Therapeutics and Genzyme.
Kate’s advisory experience includes roles as chair of the board of directors at Fulcum Therapeutics, independent director on the board of directors at Bicara Therapeutics, member of the board of directors at Biotechnology Innovation Organization (BIO) and trustee of the Boston Museum of Science.
The appointment of a new Board Chair strengthens GC’s growth plans. The company recently announced endorsements from the US Food and Drug Administration (FDA) and European Medicines Agency (EMA) for its pipeline. The pipeline includes programmes centring on demyelinating neurological disorders such as multiple sclerosis (MS), as well as a regenerative cell therapy programme for the treatment of metabolic diseases such as type 1 diabetes.
Parastoo Khoshakhlagh, co-founder and CEO of GC, said: “With Kate joining us as chair of our board, we are exceptionally well positioned to sustain our rapid growth and advance our first programme into the clinic, where we expect to unlock the full value of our platform.”
Kate added: “GC is tackling the most persistent challenges in cell therapy with a platform that is both scientifically compelling and operationally scalable. The company’s approach to cellular programming, manufacturing and regulatory strategy positions it as a leader who can meaningfully expand patient access to transformative therapies.”